



**Biocon Limited**  
20th KM, Hosur Road  
Electronic City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423  
  
CIN : L24234KA1978PLC003417  
  
[www.biocon.com](http://www.biocon.com)

BIO/SECL/SG/2024-25/120

November 07, 2024

To, The Secretary <b>BSE Limited</b> Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 <b>Scrip Code - 532523</b>	To, The Secretary <b>National Stock Exchange of India Limited</b> Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 <b>Scrip Symbol - BIOCON</b>
--	---

Dear Sir/Madam,

**Sub: Intimation of Schedule of Meeting with Analyst/Institutional Investor**

Pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), we wish to inform you that the Management of the Company is participating in an Investor Conference scheduled to be held in Mumbai on November 13, 2024. The Management will interact with the below investors at the aforesaid Investor Conference:

Date	Investor Name	Type of Meeting
13-Nov-24	Alchemy Capital Management Pvt. Ltd.	1x1/ Group/ In-person
	Awriga Capital	
	Banyan Tree Advisors	
	Canara HSBC Life Insurance	
	Dalton Investments	
	East Lane Capital	
	Entrust Family Office Investment Advisors Pvt Ltd	
	HSBC Global Asset Management (India) Private Limited	
	InCred Asset Management Private Limited	
	Indiafirst Life Insurance Company	
	Ithought Financial Consulting LLP	
	ITI Asset Management Company	
Marval Capital Ltd		

Mirae Asset Global Investments (India) Pvt. Ltd.	
Molecule Ventures	
New Mark Capital India	
Nippon Life India Asset Management Limited	
Perpetuity Investments	
PNB MetLife India Insurance Co., Ltd.	
Quest Investment Advisors (Private) Limited	
Royal Sundaram General Insurance	
Ruane Cunniff & Goldfarb	
SageOne Investment Advisors	
Sorai Advisors LLP	
Star Union Dai-chi Life Insurance	
Tree Line Advisors (Hong Kong) Ltd	

Note: The above-mentioned schedule is subject to change due to exigencies on the part of Investors/Company.

The Company will not disclose any Unpublished Price Sensitive Information (UPSI) at the upcoming analyst/investor meeting.

We request you to kindly take the above intimation on record.

Thanking You,

Yours faithfully,

For **Biocon Limited**

---

**Mayank Verma**  
**Company Secretary and Compliance Officer**  
**Membership No.: ACS 18776**